The Acute Myeloid Leukemia Channel is supported through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | ICUS, CHIP, and CCUS: practical approaches to diagnosis, risk stratification, and referral
Zhuoer Xie, MD, MS, Moffitt Cancer Center, Tampa, FL, discusses the management of patients with idiopathic cytopenia of undetermined significance (ICUS), clonal hematopoiesis of indeterminate potential (CHIP), and clonal cytopenia of undetermined significance (CCUS) in the community setting. Dr Xie highlights the importance of thoroughly evaluating unexplained cytopenias before assigning a clonal diagnosis. She also discusses the use of risk scoring tools to guide surveillance and referral to academic centers, as well as the need to address non-malignant risks associated with clonal hematopoiesis. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
